OR WAIT 15 SECS
The global immunology market-covering autoimmune diseases such as rheumatoid arthritis, psoriasis, lupus, and ankylosing spondylitis-is set to increase from $57.7 billion in 2015 to $75.4 billion by 2022, a 4% growth, according to business intelligence provider GBI Research.
The latest report from GBI states disease-modifying anti-rheumatic drugs, which is an extremely genericized class of systematic small molecule-based agents, are used in the first-line treatment of immunological disorders. However, a large second-line therapy segment has appeared in these markets, due to failure in maintaining long-term responses. This began with the approval of Remicade (infliximab) and Enbrel (etanercept) in 1998. This segment consists largely of premium systemic monoclonal antibodies (mAbs), which have been very commercially successful over the past decade.
The large immunology pipeline comprises 2,054 products in active development-almost 100 of which are in Phase III. Although none of the products in the late-stage pipeline are expected to achieve the same levels of success as the mAbs that are currently in the market, GBI Research believes the more competitive landscape will enable a number of candidates to generate strong annual revenues during the forecast period, such as sarilumab and baricitinib.